India's Cipla jumps after Citi sees near-term positive triggers for earnings
BUZZ-India's Cipla jumps after Citi sees near-term positive triggers for earnings ** Drug maker Cipla's shares CIPL.NS rise as much as 4.84% to 1,417.2 rupees in biggest intraday gain in five weeks
** Rally comes after Citi placed CIPL on 90-day positive watch, a short-term classification indicating events that are likely to boost the stock
** Citi points to possible near-term boosts from approval for a generic version of Flovent (asthma treatment), likely from its Goa plant, and the launch of generic Ventolin (respiratory treatment)
** Citi sees CIPL rising 25.6% over next 12 months
** Fresh U.S. FDA inspection and clearance of Indore plant could add another boost, Citi says
** Average rating of 37 analysts tracking CIPL is "buy"; median price target is 1,472.5 rupees, data compiled by LSEG shows
** CIPL shares are down 6.4% in 2026, underperforming pharma index's .NIPHARM 8.8% rise, exchange data shows
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated